> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pfizer Covid Oral Drug 89% Effective
- URL: https://www.fdaweb.com/pfizer-covid-oral-drug-89-effective/
- Published: 2021-12-14T12:00:00.000Z
- Updated: 2026-09-14T17:25:41.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150764

Pfizer says new data on its Covid-19 oral antiviral drug Paxlovid (nirmatrelvir tablets and ritonavir tablets) show the drug significantly reduced the risk of hospitalization or death for any cause by 89% compared to placebo in non-hospitalized, high-risk adult patients with Covid and treated within three days of symptom onset. In a secondary endpoint, it reduced the risk of hospitalization or death for any cause by 88% compared to placebo in patients treated within five days of symptom onset, an increase from the 85% observed in an earlier interim analysis, it says. The data are from the EPIC-HR clinical trial and have been shared with FDA as part of an ongoing rolling submission for an Emergency Use Authorization.